I
ImageneBio, Inc. (IMA)
NCM – Real vaqt narxi. Valyuta: USD
6.02
+0.08 (1.35%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
6.02
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 4:10 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
6.02
+0.08 (1.35%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
6.02
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 4:10 PM EDT
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
| Ism | Lavozim |
|---|---|
| Dr. Benjamin Porter-Brown M.D. | Chief Medical Officer |
| Dr. Kristin Yarema Ph.D. | CEO, Director & Interim Principal Financial Officer |
| Dr. Kurinji Pandiyan Ph.D. | Chief Strategy & Operations Officer |
| Mr. Bob Lally | Senior VP of Finance & Operations and Principal Accounting Officer |
| Ms. Renuka Sivendran Ph.D. | Chief Technical Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-26 | 8-K | d131079d8k.htm |
| 2026-05-07 | 8-K | d151394d8k.htm |
| 2026-04-30 | DEF 14A | edge20064682x1_def14a.htm |
| 2026-04-13 | 8-K | d143873d8k.htm |
| 2026-04-02 | POS AM | d254007dposam.htm |
| 2026-03-17 | 8-K | d56716d8k.htm |
| 2026-03-10 | S-8 | d107848ds8.htm |
| 2026-03-10 | 8-K | d130344d8k.htm |
| 2026-03-10 | 10-K | ima-20251231.htm |
| 2026-02-17 | 8-K | d18298d8k.htm |